ACH471-001; A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0144471 in Healthy Volunteers.

Trial Profile

ACH471-001; A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0144471 in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; First in man
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2016 Status changed from recruiting to completed.
    • 10 Jun 2016 According to an Achillion Pharmaceuticals media release, interim results (n=36) of this trial were presented at the 21st Congress of the European Hematology Association 2016.
    • 10 Jun 2016 Interim results (n=36) published in an Achillion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top